Disproportionality analysis of adverse events associated with degarelix: a real-world study from the FDA Adverse Event Reporting System (FAERS) database.
This study reveals potential new risks associated with degarelix, including AEs not listed on the drug label, emphasizing the need for ongoing safety monitoring.
Where it sits
this study against the rest of the degarelix corpusSummary and findings
This study analyzed adverse events (AEs) associated with degarelix using the FDA Adverse Event Reporting System (FAERS) from January 2014 to December 2024. A total of 2,984 AEs were reported, with 130 Preferred Terms showing significant disproportionate reporting. The study identified potential new risks not listed on the drug label.
Abstract
<h4>Purpose</h4>This study aimed to detect adverse event (AE) signals associated with degarelix by analyzing data from the US FDA Adverse Event Reporting System (FAERS), so as to provide evidence for its safe clinical use.<h4>Methods</h4>Data from the FAERS database spanning January 2014 to December 2024 were extracted, cleaned, and deduplicated. A disproportionality analysis was performed to identify significant AE signals by calculating and comparing four established metrics: the Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), the Information Component of the Bayesian Confidence Propagation Neural Network (BCPNN), and the Empirical Bayes Geometric Mean (EBGM). Statistical significance for signal detection was defined as exceeding the predefined thresholds for each respective metric. AEs were coded with the Medical Dictionary for Regulatory Activities (MedDRA).<h4>Results</h4>Among 17,048,812 AE reports recorded in FAERS during the study period, 2,984 were associated with degarelix. These reports spanned 22 System Organ Classes (SOC), and 130 Preferred Terms (PTs) showed significant disproportionate reporting based on the four algorithms. Injection site reactions and hot flush were consistent with common AEs listed in the label. It is noteworthy that 53 AEs, such as interstitial lung disease, cardiac failure, osteoporotic fracture, and hyperkalaemia, were absent from the label and may represent previously unreported risks that warrant further study.<h4>Conclusion</h4>Our findings not only validate the established safety data for degarelix but also reveal potential new risks, necessitating continued post-marketing vigilance to guide its safer clinical application.
Background
This paper addresses the safety profile of degarelix, a medication used in the treatment of prostate cancer, by analyzing adverse events reported in the FAERS database. Prior studies have established a safety profile for degarelix, but ongoing monitoring is essential to identify any new risks. The significance of this study lies in its potential to uncover previously unreported adverse events associated with the drug.
Methods
The study utilized a disproportionality analysis of data extracted from the FAERS database, covering reports from January 2014 to December 2024. A total of 2,984 AEs associated with degarelix were analyzed using four metrics: Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Information Component of Bayesian Confidence Propagation Neural Network (BCPNN), and Empirical Bayes Geometric Mean (EBGM). Statistical significance was defined by exceeding predefined thresholds for each metric.
Results
Among 17,048,812 AE reports, 2,984 were associated with degarelix. The analysis identified 130 Preferred Terms with significant disproportionate reporting. Notably, 53 AEs, including interstitial lung disease and cardiac failure, were not listed on the drug label.
Interpretation
The findings align with existing safety data for degarelix while also highlighting new potential risks that were not previously documented. Although the study identifies statistically significant AEs, the clinical significance of these findings requires further investigation. Limitations include the reliance on reported data, which may not capture the full spectrum of adverse events, and the potential for bias in reporting.
Key findings
- 2,984 AEs associated with degarelix from 17,048,812 total reports in FAERS.
- 130 Preferred Terms showed significant disproportionate reporting based on four algorithms.
- 53 AEs, including interstitial lung disease and cardiac failure, were absent from the drug label.
Limitations
- Analysis based on reported data, subject to underreporting.
- Does not establish causation between degarelix and identified AEs.
- Potential for bias in adverse event reporting.